Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-03-11
2000-01-18
Crane, L. Eric
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 49, 514 50, 514269, 514 54, 536 11, 536 221, 536124, 435101, 435134, 424 92, A61K 3170
Patent
active
060157968
ABSTRACT:
The present invention relates to a method for treating AIDS, which comprises administering to an HIV-infected patient (a) a composition containing as the primary component a polysaccharide derived from a hot water extract of human-type tubercle bacillus and (b) a nucleoside-type anti-HIV agent. Due to the incorporation of composition (a), the present invention enhances the therapeutic effect of nucleoside-type anti-HIV agents on AIDS.
REFERENCES:
patent: 4746511 (1988-05-01), Kobatake et al.
patent: 5521161 (1996-05-01), Malley et al.
Arp et al., "Expression and Immunogenicity of the Entire Human T Cell Leukemia Virus Type I Envelope Protein Produced in a Baculovirus System", Journal of General Virology, 74(2), 211-222 (1993).
Okunade et al., "Antimicrobial Properties of Alkaloids from Xanthorhize Simplicissima, " Journal of Pharmaceutical Sciences, 83(2), 404-406 (Mar. 1994).
Guleria et al., "Auxotropic Vaccines for Tuberculosis," Nature Medicine (New York), 2(3), 334-337 (1996).
Ishihara et al., "Phase II Clinical Trial of MY-1 for Adult T Cell Leukemia," Skin Cancer, 10(2), 257-270 (1995); only Abstract provided.
Bernier et al., "Mycobacterium Tuberculosis Mannose-Capped Lipoarabinomannan Can Induce NR-kappaB-Dependent Activation of Human Immunodeficiency Virus Type 1 Long Terminal Repeat in T Cells," J. General Virology, 79(pt. 6), 1353-1361 (Jun., 1998).
"Diagnostics--Mycobacterium Avium," AIDS Weekly, Issue of Nov. 28, 1994, only 349 word abstract provided, page location(s) not available.
Vila et al., "Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine and Hydroxycarbamide," The Lancet, 350, 635-636 (Aug. 30, 1997).
Yoshiro Hayashi, et al., Biotherapy, vol. 7, pp. 63-69, "The Effect of Combination Therapy of Radiation and Z-100, and Arabinomannan on Tumor Growth in Mice", 1994.
Hideki Ohnota, et al., Antimicrobial Agents and Chemotherapy, vol. 34, No. 4, pp. 605-609, "3 -Azido-3'-Deoxythymidine Prevents Induction of Murine Acquired Immunodeficiency Syndrome in C57BL/10 Mice Infected with LP-BM5 Murine Leukemia Viruses, A Possible Animal Model for Antiretroviral Drug Screening", Apr. 1990.
Osamu Ohya, et al, The Clinical Report, vol. 24 No 4, pp. 441-448, "Hematopoietic Effect of Z-100, An Extract From Human Type Tubercle Bacilli (2)--Therapeutic Effect on the Hematological and Immunological Damage in X-Ray Irradiated Mice", (with English Summary) (Mar. 1990).
M. Kobayashi, et al., The 1995 UCLA/UCI AIDS Symposium, p. 40, "Mechanisms of HIV Disease", Mar. 2-5, 1995, Palm Springs, CA, Hyatt Regency Suites.
Kobayashi Makiko
Sasaki Hidetaka
Suzuki Fujio
Crane L. Eric
Natsu Maruyama
Zeria Pharmaceutical Co. Ltd.
LandOfFree
Method for treating AIDS does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating AIDS, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating AIDS will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-563479